News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nuvilex Engages Virusure To Establish Cell Banks For Phase 2b Clinical Trials In Pancreatic Cancer



4/10/2014 7:34:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SILVER SPRING, Md., April 10, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that it has signed a Master Services Agreement with ViruSure GmbH, located in Vienna, Austria, to develop and maintain Master, Working and End of Production Cell Banks. These cell banks are necessary steps in the production of the cells to be encapsulated using the Cell-in-a-Box® technology for Nuvilex's Phase 2b clinical trials in advanced, inoperable pancreatic cancer to be conducted in Australia.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Nuvilex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES